Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance
Opinion statement Cytogenetics and mutation identification in acute myeloid leukemia have allowed for more targeted therapy. Many therapies have been approved by the FDA in the last 3 years including gilteritinib and azacitidine but the overall survival has remained stagnant at 25%. The inability to...
Gespeichert in:
| Veröffentlicht in: | Current treatment options in oncology 2021-09, Vol.22 (9), p.76-76, Article 76 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 76 |
|---|---|
| container_issue | 9 |
| container_start_page | 76 |
| container_title | Current treatment options in oncology |
| container_volume | 22 |
| creator | Uddin, Rehan Darwish, Noureldian H. E. Mousa, Shaker A. |
| description | Opinion statement
Cytogenetics and mutation identification in acute myeloid leukemia have allowed for more targeted therapy. Many therapies have been approved by the FDA in the last 3 years including gilteritinib and azacitidine but the overall survival has remained stagnant at 25%. The inability to achieve complete remission was related to the residual leukemic stem cells (LSCs). Thus, the relationship between bone marrow niche and LSCs must be further explored to prevent treatment relapse/resistance. The development of immunotherapy and nanotechnology may play a role in future therapy to achieve the complete remission. Nano-encapsulation of drugs can improve drugs’ bioavailability, help drugs evade resistance, and provide combination therapy directly to the cancer cells. Studies indicate targeting surface antigens such as CLL1 and CD123 using chimeric antibody receptor T cells can improve survival outcomes. Finally, new discoveries indicate that inhibiting integrin αvβ3 and acid ceramidase may prove to be efficacious. |
| doi_str_mv | 10.1007/s11864-021-00880-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2548409981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2547980330</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-5ee11c45bb81ed2d32cf86161e94b604919d416748d0b4b976d66140b38965313</originalsourceid><addsrcrecordid>eNp9kElPHDEQRq0oUViSP5ADspRLLk1cttvLEaGwSIOQIjhbbncNaZjuBi8I_j0ehoDEgVNZqldfuR4hP4DtA2P6dwIwSjaMQ8OYMax5-ES2oRWyUVzrz-s31w3X3G6RnZSuGeOtZPYr2RKSg1CGb5PLg1Ay0rNHXM1DTxdYbnAcPD0r2edhnhL1U0-PSi6xUhj--WlIeQj0wscrzDTP9PweY5hHpH8x1Z6fAn4jX5Z-lfD7S90ll0d_Lg5PmsX58enhwaIJQre5aREBgmy7zgD2vBc8LI0CBWhlp5i0YHsJSkvTs052VqteKZCsE8aqVoDYJb82ubdxviuYshuHFHC18hPOJbl6r6kXW7NGf75Dr-cSp_q7NaWtYUKwSvENFeKcUsSlu43D6OOjA-bW0t1GuqvS3bN091CH9l6iSzdi_zry33IFxAZItTVdYXzb_UHsE5PIi5A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547980330</pqid></control><display><type>article</type><title>Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Uddin, Rehan ; Darwish, Noureldian H. E. ; Mousa, Shaker A.</creator><creatorcontrib>Uddin, Rehan ; Darwish, Noureldian H. E. ; Mousa, Shaker A.</creatorcontrib><description>Opinion statement
Cytogenetics and mutation identification in acute myeloid leukemia have allowed for more targeted therapy. Many therapies have been approved by the FDA in the last 3 years including gilteritinib and azacitidine but the overall survival has remained stagnant at 25%. The inability to achieve complete remission was related to the residual leukemic stem cells (LSCs). Thus, the relationship between bone marrow niche and LSCs must be further explored to prevent treatment relapse/resistance. The development of immunotherapy and nanotechnology may play a role in future therapy to achieve the complete remission. Nano-encapsulation of drugs can improve drugs’ bioavailability, help drugs evade resistance, and provide combination therapy directly to the cancer cells. Studies indicate targeting surface antigens such as CLL1 and CD123 using chimeric antibody receptor T cells can improve survival outcomes. Finally, new discoveries indicate that inhibiting integrin αvβ3 and acid ceramidase may prove to be efficacious.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-021-00880-x</identifier><identifier>PMID: 34213682</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acute myeloid leukemia ; Antigens ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bioavailability ; Biomarkers, Tumor ; Bone marrow ; CD123 antigen ; Ceramidase ; Combined Modality Therapy - methods ; Cytogenetics ; Disease Susceptibility ; Drug resistance ; Drug Resistance, Neoplasm - genetics ; Gene Expression Regulation, Leukemic - drug effects ; Humans ; Immunotherapy ; Leukemia ; Leukemia (PH Wiernik ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - therapy ; Lymphocytes T ; Medicine ; Medicine & Public Health ; Molecular Targeted Therapy - adverse effects ; Molecular Targeted Therapy - methods ; Mutation ; Myeloid leukemia ; Nanomedicine ; Oncology ; Precision Medicine ; Remission ; Section Editor ; Stem cells ; Surface antigens ; Topical Collection on Leukemia ; Treatment Outcome ; Tumor Microenvironment - drug effects ; Tumor Microenvironment - genetics ; Tumor Microenvironment - immunology</subject><ispartof>Current treatment options in oncology, 2021-09, Vol.22 (9), p.76-76, Article 76</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-5ee11c45bb81ed2d32cf86161e94b604919d416748d0b4b976d66140b38965313</citedby><cites>FETCH-LOGICAL-c375t-5ee11c45bb81ed2d32cf86161e94b604919d416748d0b4b976d66140b38965313</cites><orcidid>0000-0002-9294-015X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11864-021-00880-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11864-021-00880-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34213682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uddin, Rehan</creatorcontrib><creatorcontrib>Darwish, Noureldian H. E.</creatorcontrib><creatorcontrib>Mousa, Shaker A.</creatorcontrib><title>Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion statement
Cytogenetics and mutation identification in acute myeloid leukemia have allowed for more targeted therapy. Many therapies have been approved by the FDA in the last 3 years including gilteritinib and azacitidine but the overall survival has remained stagnant at 25%. The inability to achieve complete remission was related to the residual leukemic stem cells (LSCs). Thus, the relationship between bone marrow niche and LSCs must be further explored to prevent treatment relapse/resistance. The development of immunotherapy and nanotechnology may play a role in future therapy to achieve the complete remission. Nano-encapsulation of drugs can improve drugs’ bioavailability, help drugs evade resistance, and provide combination therapy directly to the cancer cells. Studies indicate targeting surface antigens such as CLL1 and CD123 using chimeric antibody receptor T cells can improve survival outcomes. Finally, new discoveries indicate that inhibiting integrin αvβ3 and acid ceramidase may prove to be efficacious.</description><subject>Acute myeloid leukemia</subject><subject>Antigens</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bioavailability</subject><subject>Biomarkers, Tumor</subject><subject>Bone marrow</subject><subject>CD123 antigen</subject><subject>Ceramidase</subject><subject>Combined Modality Therapy - methods</subject><subject>Cytogenetics</subject><subject>Disease Susceptibility</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Gene Expression Regulation, Leukemic - drug effects</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Leukemia</subject><subject>Leukemia (PH Wiernik</subject><subject>Leukemia, Myeloid, Acute - diagnosis</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Lymphocytes T</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Molecular Targeted Therapy - adverse effects</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Mutation</subject><subject>Myeloid leukemia</subject><subject>Nanomedicine</subject><subject>Oncology</subject><subject>Precision Medicine</subject><subject>Remission</subject><subject>Section Editor</subject><subject>Stem cells</subject><subject>Surface antigens</subject><subject>Topical Collection on Leukemia</subject><subject>Treatment Outcome</subject><subject>Tumor Microenvironment - drug effects</subject><subject>Tumor Microenvironment - genetics</subject><subject>Tumor Microenvironment - immunology</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kElPHDEQRq0oUViSP5ADspRLLk1cttvLEaGwSIOQIjhbbncNaZjuBi8I_j0ehoDEgVNZqldfuR4hP4DtA2P6dwIwSjaMQ8OYMax5-ES2oRWyUVzrz-s31w3X3G6RnZSuGeOtZPYr2RKSg1CGb5PLg1Ay0rNHXM1DTxdYbnAcPD0r2edhnhL1U0-PSi6xUhj--WlIeQj0wscrzDTP9PweY5hHpH8x1Z6fAn4jX5Z-lfD7S90ll0d_Lg5PmsX58enhwaIJQre5aREBgmy7zgD2vBc8LI0CBWhlp5i0YHsJSkvTs052VqteKZCsE8aqVoDYJb82ubdxviuYshuHFHC18hPOJbl6r6kXW7NGf75Dr-cSp_q7NaWtYUKwSvENFeKcUsSlu43D6OOjA-bW0t1GuqvS3bN091CH9l6iSzdi_zry33IFxAZItTVdYXzb_UHsE5PIi5A</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Uddin, Rehan</creator><creator>Darwish, Noureldian H. E.</creator><creator>Mousa, Shaker A.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9294-015X</orcidid></search><sort><creationdate>20210901</creationdate><title>Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance</title><author>Uddin, Rehan ; Darwish, Noureldian H. E. ; Mousa, Shaker A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-5ee11c45bb81ed2d32cf86161e94b604919d416748d0b4b976d66140b38965313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute myeloid leukemia</topic><topic>Antigens</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bioavailability</topic><topic>Biomarkers, Tumor</topic><topic>Bone marrow</topic><topic>CD123 antigen</topic><topic>Ceramidase</topic><topic>Combined Modality Therapy - methods</topic><topic>Cytogenetics</topic><topic>Disease Susceptibility</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Gene Expression Regulation, Leukemic - drug effects</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Leukemia</topic><topic>Leukemia (PH Wiernik</topic><topic>Leukemia, Myeloid, Acute - diagnosis</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Lymphocytes T</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Molecular Targeted Therapy - adverse effects</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Mutation</topic><topic>Myeloid leukemia</topic><topic>Nanomedicine</topic><topic>Oncology</topic><topic>Precision Medicine</topic><topic>Remission</topic><topic>Section Editor</topic><topic>Stem cells</topic><topic>Surface antigens</topic><topic>Topical Collection on Leukemia</topic><topic>Treatment Outcome</topic><topic>Tumor Microenvironment - drug effects</topic><topic>Tumor Microenvironment - genetics</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uddin, Rehan</creatorcontrib><creatorcontrib>Darwish, Noureldian H. E.</creatorcontrib><creatorcontrib>Mousa, Shaker A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uddin, Rehan</au><au>Darwish, Noureldian H. E.</au><au>Mousa, Shaker A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>22</volume><issue>9</issue><spage>76</spage><epage>76</epage><pages>76-76</pages><artnum>76</artnum><issn>1527-2729</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>Opinion statement
Cytogenetics and mutation identification in acute myeloid leukemia have allowed for more targeted therapy. Many therapies have been approved by the FDA in the last 3 years including gilteritinib and azacitidine but the overall survival has remained stagnant at 25%. The inability to achieve complete remission was related to the residual leukemic stem cells (LSCs). Thus, the relationship between bone marrow niche and LSCs must be further explored to prevent treatment relapse/resistance. The development of immunotherapy and nanotechnology may play a role in future therapy to achieve the complete remission. Nano-encapsulation of drugs can improve drugs’ bioavailability, help drugs evade resistance, and provide combination therapy directly to the cancer cells. Studies indicate targeting surface antigens such as CLL1 and CD123 using chimeric antibody receptor T cells can improve survival outcomes. Finally, new discoveries indicate that inhibiting integrin αvβ3 and acid ceramidase may prove to be efficacious.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34213682</pmid><doi>10.1007/s11864-021-00880-x</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9294-015X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-2729 |
| ispartof | Current treatment options in oncology, 2021-09, Vol.22 (9), p.76-76, Article 76 |
| issn | 1527-2729 1534-6277 1534-5277 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2548409981 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Acute myeloid leukemia Antigens Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bioavailability Biomarkers, Tumor Bone marrow CD123 antigen Ceramidase Combined Modality Therapy - methods Cytogenetics Disease Susceptibility Drug resistance Drug Resistance, Neoplasm - genetics Gene Expression Regulation, Leukemic - drug effects Humans Immunotherapy Leukemia Leukemia (PH Wiernik Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - therapy Lymphocytes T Medicine Medicine & Public Health Molecular Targeted Therapy - adverse effects Molecular Targeted Therapy - methods Mutation Myeloid leukemia Nanomedicine Oncology Precision Medicine Remission Section Editor Stem cells Surface antigens Topical Collection on Leukemia Treatment Outcome Tumor Microenvironment - drug effects Tumor Microenvironment - genetics Tumor Microenvironment - immunology |
| title | Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A27%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20Myeloid%20Leukemia%20Mutations%20and%20Future%20Mechanistic%20Target%20to%20Overcome%20Resistance&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Uddin,%20Rehan&rft.date=2021-09-01&rft.volume=22&rft.issue=9&rft.spage=76&rft.epage=76&rft.pages=76-76&rft.artnum=76&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-021-00880-x&rft_dat=%3Cproquest_cross%3E2547980330%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547980330&rft_id=info:pmid/34213682&rfr_iscdi=true |